Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone

Molecular Medicine Reports

Volumn 13, Issue 6, 2016, Pages 4549-4560

  Salido Guadarrama, Alberto Ivan ^a   Morales Montor, Jorge Gustavo ^b   Rangel Escareño, Claudia ^a   Langley, Elizabeth ^c   Peralta Zaragoza, Oscar ^d   Colin, Jose Luis Cruz ^a   Rodriguez Dorantes, Mauricio ^a  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

MicroRNA; Prostate cancer; Prostate specific antigen grey zone; Urine

Indexed keywords

MICRORNA 100; MICRORNA 200B; PROSTATE SPECIFIC ANTIGEN; MICRORNA; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GENE EXPRESSION PROFILING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEXICAN; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR DIFFERENTIATION; URINALYSIS; URINE; VALIDATION STUDY; BIOPSY; CANCER GRADING; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; ODDS RATIO; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; RNA STABILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA STABILITY; ROC CURVE; TRANSCRIPTOME;

EID: 84966593292     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5095     Document Type: Article

References (44)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB and Nelson WG: Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 91: 459-477, 2004.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328, 2009.
4. Shappell SB: Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol 10: 44-69, 2008.
5. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C and Soloway MS: Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol 62: 976-983, 2012.
6. Romero Otero J, Garcia Gomez B, Campos Juanatey F and Touijer KA: Prostate cancer biomarkers: An update. Urol Oncol 32: 252-260, 2014.
7. Mao G, Liu Y, Fang X, Liu Y, Fang L, Lin L, Liu X and Wang N: Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer. Angiogenesis 18: 373-382, 2015.
8. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, et al: A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867, 2007.
9. Katz B, Reis ST, Viana NI, Morais DR, Moura CM, Dip N, Silva IA, Iscaife A, Srougi M and Leite KR: Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS One 9: e113700, 2014.
10. Wang Y, Kim S and Kim IM: Regulation of Metastasis by microRNAs in Ovarian Cancer. Front Oncol 4: 143, 2014.
11. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta 1845: 255-265, 2014.
12. Fang YX and Gao WQ: Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 33: 135-147, 2014.
13. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170, 2008.
14. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007.
15. Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda A and Rodriguez-Dorantes M: MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther 7: 1327-1338, 2014.
16. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P and Blelloch R: Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71: 550-560, 2011.
17. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R and Sültmann H: Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128: 608-616, 2011.
18. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E and Wong DT: Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15: 5473-5477, 2009.
19. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, et al: MicroRNA profiling in prostate cancer-The diagnostic potential of urinary MIR-205 and MIR-214. PLoS One 8: e76994, 2013.
20. Sapre N, Hong MK, Macintyre G, Lewis H, Kowalczyk A, Costello AJ, Corcoran NM and Hovens CM: Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One 9: e91729, 2014.
21. Eissa S, Habib H, Ali E and Kotb Y: Evaluation of urinary miRNA-96 as a potential biomarker for bladder cancer diagnosis. Med Oncol 32: 413, 2015.
22. Haj-Ahmad TA, Abdalla MA and Haj-Ahmad Y: Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 5: 182-191, 2014.
23. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, et al: APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095, 2006.
24. Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R and Esquela-Kerscher A: MIR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle 13: 227-239, 2014.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
26. Suyundikov A Stevens JR, Corcoran C, Herrick J, Wolff RK and Slattery ML: Incorporation of subject-level covariates in quantile normalization of miRNA data. BMC Genomics 16: 1045, 2015.
27. Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, Giannarini G, Kibel AS, Montironi R, Ploussard G, et al: Contemporary role of systematic prostate biopsies: Indications, techniques, and implications for patient care. Eur Urol 63: 214-230, 2013.
28. Loeb S, Han M, Roehl KA, Antenor JA and Catalona WJ: Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. J Urol 173: 63-65, 2005.
29. Levy DA and Jones JS: Management of rising prostate-specific antigen after a negative biopsy. Curr Urol Rep 12: 197-202, 2011.
30. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z and Bouchal J: Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 13: 12-19, 2010.
31. Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M and Duensing S: Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol 33: 16.e17-e22, 2015.
32. Stephan C, Jung M, Rabenhorst S, Kilic E and Jung K: Urinary MIR-183 and MIR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. Clin Chem Lab Med 53: 1109-1118, 2015.
33. Kim J, Morley S, Le M, Bedoret D, Umetsu DT, Di Vizio D and Freeman MR: Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: Potential effects on the tumor microenvironment. Cancer Biol Ther 15: 409-418, 2014.
34. Hessvik NP, Phuyal S, Brech A, Sandvig K and Llorente A: Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta 1819: 1154-1163, 2012.
35. Schröder FH, Raaijmakers R, Postma R, van der Kwast TH and Roobol MJ: 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 174: 489-494; discussion 493-494, 2005.
36. Fitzgerald M, Saville BR and Lewis RJ: Decision curve analysis. JAMA 313: 409-410, 2015.
37. Tomlins SA: Urine PCA3 and TMPRSS2: ERG using cancer-specific markers to detect cancer. Eur Urol 65: 543-545, 2014.
38. Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F and Cussenot O: Urine TMPRSS2: ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 73: 242-249, 2013.
39. Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ and Hessels D: Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58: 475-481, 2010.
40. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Camara-Lopes LH and Srougi M: MicroRNA expression profiles in the progression of prostate cancer - from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 31: 796-801, 2013.
41. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Dall'Oglio MF, Camara-Lopes LH and Srougi M: MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 185: 1118-1122, 2011.
42. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, et al: Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 8: e69239, 2013.
43. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
44. Mueller AC, Sun D and Dutta A: The MIR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 32: 1164-1172, 2013.